{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplastic+Processes&page=11", "query": { "condition": "Neoplastic Processes", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 2532, "total_pages": 254, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplastic+Processes&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplastic+Processes&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T04:12:08.675Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00068068", "title": "Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Metastasis", "Colorectal Neoplasms", "Liver Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Talaporfin sodium (LS11)", "type": "DRUG" }, { "name": "LED-based light infusion device", "type": "DEVICE" }, { "name": "Light emitting diodes (LED)", "type": "DEVICE" }, { "name": "Photodynamic therapy", "type": "PROCEDURE" }, { "name": "Phototherapy", "type": "PROCEDURE" }, { "name": "Chemotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "Light Sciences LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2003-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-09-19", "last_synced_at": "2026-10-29T04:12:08.675Z", "location_count": 5, "location_summary": "Denver, Colorado • Greenville, North Carolina • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Greenville", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068068" }, { "nct_id": "NCT00041808", "title": "Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastases, Neoplasm", "Colorectal Neoplasms", "Esophageal Neoplasms", "Stomach Neoplasms", "Pancreatic Neoplasms", "Breast Neoplasms", "Melanoma", "Sarcoma", "Gastrointestinal Neoplasms", "Lung Neoplasms", "Liver Neoplasms", "Cholangiocarcinoma" ], "interventions": [ { "name": "MTC-DOX for Injection", "type": "DRUG" }, { "name": "Chemotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "FeRx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2001-07", "completion_date": "2003-04", "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-29T04:12:08.675Z", "location_count": 3, "location_summary": "San Diego, California • San Francisco, California • Temple, Texas", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00041808" }, { "nct_id": "NCT07364474", "title": "Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "Melphalan through Percutaneous Hepatic Perfusion", "type": "DRUG" }, { "name": "Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-01-27", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-29T04:12:08.675Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07364474" }, { "nct_id": "NCT01322490", "title": "A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "PROSTVAC-V", "type": "BIOLOGICAL" }, { "name": "PROSTVAC-F", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "GM-CSF Placebo", "type": "OTHER" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1297, "start_date": "2011-11-28", "completion_date": "2017-12-15", "has_results": true, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-10-29T04:12:08.675Z", "location_count": 84, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Berkeley, California + 68 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Marina del Rey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01322490" }, { "nct_id": "NCT01957735", "title": "BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Cancer", "Solid Tumor" ], "interventions": [ { "name": "BP31510 monotherapy", "type": "DRUG" }, { "name": "BP31510 in combination with chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BPGbio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2013-10", "completion_date": "2017-02-01", "has_results": false, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-10-29T04:12:08.675Z", "location_count": 3, "location_summary": "Sunnyvale, California • New York, New York • Houston, Texas", "locations": [ { "city": "Sunnyvale", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01957735" }, { "nct_id": "NCT01858740", "title": "Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Biphenotypic Leukemia", "Acute Leukemia of Ambiguous Lineage", "Acute Undifferentiated Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Myelodysplastic Syndrome With Excess Blasts-1", "Myelodysplastic Syndrome With Excess Blasts-2", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Refractory Adult Acute Lymphoblastic Leukemia", "Refractory Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "T Cell-Depleted Hematopoietic Stem Cell Transplantation", "type": "BIOLOGICAL" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 20, "start_date": "2014-04-10", "completion_date": "2023-07-30", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-29T04:12:08.675Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01858740" }, { "nct_id": "NCT00047840", "title": "This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line" ], "interventions": [ { "name": "ZD6474", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2002-10", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2016-08-25", "last_synced_at": "2026-10-29T04:12:08.675Z", "location_count": 16, "location_summary": "Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047840" }, { "nct_id": "NCT04514497", "title": "Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Neuroendocrine Carcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Lung Small Cell Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Neuroendocrine Carcinoma", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Elimusertib", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2021-10-20", "completion_date": "2027-03-04", "has_results": true, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-29T04:12:08.675Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Trumbull", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04514497" }, { "nct_id": "NCT01633060", "title": "A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" }, { "name": "BKM120 matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 432, "start_date": "2012-10-03", "completion_date": "2017-09-21", "has_results": true, "last_update_posted_date": "2019-01-30", "last_synced_at": "2026-10-29T04:12:08.675Z", "location_count": 37, "location_summary": "Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 24 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01633060" }, { "nct_id": "NCT03096782", "title": "Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Biphenotypic Leukemia", "Acute Leukemia", "Acute Lymphoblastic Leukemia", "Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Chemotherapy-Related Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Hodgkin Lymphoma", "Langerhans Cell Histiocytosis", "Minimal Residual Disease", "Myelodysplastic Syndrome", "Myelodysplastic Syndrome With Excess Blasts", "Non-Hodgkin Lymphoma", "Recurrent Hodgkin Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Myelodysplastic Syndrome", "Small Lymphocytic Lymphoma", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim-sndz", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2017-10-13", "completion_date": "2022-09-20", "has_results": true, "last_update_posted_date": "2023-10-11", "last_synced_at": "2026-10-29T04:12:08.675Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03096782" } ] }